A phase II, open-label, multicenter study to evaluate the...

Pancreatology 2014 / 09 Vol. 14; Iss. 5

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

Li, D., Pant, S., Ryan, D.P., Laheru, D., Bahary, N., Dragovich, T., Hosein, P.J., Rolfe, L., Saif, M.W., LaValle, J., Yu, K.H., Lowery, M.A., Allen, A., O'Reilly, E.M.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
14
Language:
english
Journal:
Pancreatology
DOI:
10.1016/j.pan.2014.07.003
Date:
September, 2014
File:
PDF, 222 KB
english, 2014
Conversion to is in progress
Conversion to is failed